Sabra Health Care REIT (SBRA) Stock Overview
Operates as a self-administered, self-managed real estate investment trust that, through its subsidiaries, owns and invests in real estate serving the healthcare industry throughout the United States and Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 1/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
SBRA Community Fair Values
Create NarrativeSee what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Sabra Health Care REIT, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$18.05 |
| 52 Week High | US$21.28 |
| 52 Week Low | US$17.17 |
| Beta | 0.63 |
| 1 Month Change | -13.76% |
| 3 Month Change | -10.82% |
| 1 Year Change | -1.26% |
| 3 Year Change | 53.88% |
| 5 Year Change | 0.33% |
| Change since IPO | 11.42% |
Recent News & Updates
Narrative Update • Jun 16
SBRA: Sector Repricing And Lower Discount Rate Will Support 2026 Upside
The analyst fair value estimate for Sabra Health Care REIT has moved slightly higher to $22.77 from $22.69, as analysts factor in updated price targets across the sector along with modest adjustments to revenue growth, discount rate assumptions, profit margin expectations, and future P/E multiples. Analyst Commentary Recent Street research has centered on modestly higher price targets for Sabra Health Care REIT, which helps explain the small upward move in the overall fair value estimate.Narrative Update • Jun 02
SBRA: Senior Housing Occupancy And Yield Spread Will Drive 2026 Upside
Sabra Health Care REIT’s analyst price target is updated to $22.69 from $22.00, as analysts revise their models following a series of Street target increases clustered around $22 to $25, supported by recent sector wide REIT reviews and Q1 updates. Analyst Commentary Recent Street research on Sabra Health Care REIT clusters in the US$22 to US$25 price target range, reflecting a mix of optimism around execution and some caution on growth and valuation risk.Seeking Alpha • May 17
Sabra Health Care REIT A Buy, As Q1 Results Show Portfolio Growth
Summary Sabra Health Care REIT is rated a buy, reflecting portfolio growth, reasonable valuation, and robust geographic diversification. SBRA demonstrates strong revenue and NOI growth but faces declining EBITDA margins and flat long-term dividend growth, tempering its income appeal. The REIT maintains an investment-grade balance sheet, modest debt-to-equity, low operator concentration, and adequate AFFO dividend coverage with a 5.6% yield. Technical momentum remains bullish, with an +8% upside forecast by 2027, though sector risks include rising labor costs and potential shifts toward home healthcare. Read the full article on Seeking AlphaRecent updates
Narrative Update • Jun 16
SBRA: Sector Repricing And Lower Discount Rate Will Support 2026 Upside
The analyst fair value estimate for Sabra Health Care REIT has moved slightly higher to $22.77 from $22.69, as analysts factor in updated price targets across the sector along with modest adjustments to revenue growth, discount rate assumptions, profit margin expectations, and future P/E multiples. Analyst Commentary Recent Street research has centered on modestly higher price targets for Sabra Health Care REIT, which helps explain the small upward move in the overall fair value estimate.Narrative Update • Jun 02
SBRA: Senior Housing Occupancy And Yield Spread Will Drive 2026 Upside
Sabra Health Care REIT’s analyst price target is updated to $22.69 from $22.00, as analysts revise their models following a series of Street target increases clustered around $22 to $25, supported by recent sector wide REIT reviews and Q1 updates. Analyst Commentary Recent Street research on Sabra Health Care REIT clusters in the US$22 to US$25 price target range, reflecting a mix of optimism around execution and some caution on growth and valuation risk.Seeking Alpha • May 17
Sabra Health Care REIT A Buy, As Q1 Results Show Portfolio Growth
Summary Sabra Health Care REIT is rated a buy, reflecting portfolio growth, reasonable valuation, and robust geographic diversification. SBRA demonstrates strong revenue and NOI growth but faces declining EBITDA margins and flat long-term dividend growth, tempering its income appeal. The REIT maintains an investment-grade balance sheet, modest debt-to-equity, low operator concentration, and adequate AFFO dividend coverage with a 5.6% yield. Technical momentum remains bullish, with an +8% upside forecast by 2027, though sector risks include rising labor costs and potential shifts toward home healthcare. Read the full article on Seeking AlphaNarrative Update • Apr 30
SBRA: Occupancy Trends And Development Discipline Will Shape Confidence In 2026 Outlook
Sabra Health Care REIT's analyst price target has shifted up modestly from $21.92 to $22.00 as analysts factor in updated expectations around revenue growth, profit margins and forward P/E assumptions, supported by recent price target increases across several research firms. Analyst Commentary Recent research updates show a cluster of higher price targets for Sabra Health Care REIT in the low to mid US$20 range, with differing views on how much upside is left based on occupancy, development returns and funds from operations guidance.Narrative Update • Apr 15
SBRA: Occupancy Recovery And Investment Spreads Will Shape Confidence In 2026 Outlook
Sabra Health Care REIT's analyst price targets have moved higher, with several firms lifting their views by $1 to $3 per share to around the low to mid $20s. Analysts cite improved senior housing occupancy potential, better investment yield spreads relative to cost of capital, and updated post Q4 estimates as key supports.Narrative Update • Apr 01
SBRA: Senior Housing Occupancy Recovery Will Drive Confidence In 2026 FFO Outlook
Sabra Health Care REIT's analyst price target has edged higher to about $21.92 from $21.85, as analysts point to stronger potential revenue growth and improved senior housing occupancy prospects, partly offset by slightly softer profit margin expectations. Analyst Commentary Recent Street research on Sabra Health Care REIT has centered on refreshed valuation work following Q4 results, with several firms adjusting price targets and revisiting their views on occupancy trends, capital deployment, and funds from operations guidance.Narrative Update • Mar 18
SBRA: Senior Housing Occupancy And 2026 FFO Guidance Will Shape Balanced Outlook
Analysts have raised the fair value estimate for Sabra Health Care REIT by about $0.15 to $21.85, reflecting a mix of updated price targets in the $21 to $24 range and expectations for improving senior housing occupancy and investment yield spreads. Analyst Commentary Recent Street research on Sabra Health Care REIT centers on a cluster of higher price targets, mainly in the US$21 to US$24 range, with most firms keeping neutral or Hold style ratings and a few maintaining Buy views.Narrative Update • Mar 03
SBRA: External Acquisition Plans And 2026 FFO Guidance Will Shape Balanced Outlook
The analyst price target for Sabra Health Care REIT in our model has shifted modestly higher to $21.69. Analysts point to updated Q4 research that emphasizes near term funds from operations per share support and a preference for external growth through acquisitions.Narrative Update • Feb 17
SBRA: Higher 2026 FFO Guidance And Richer P/E Assumptions Shape Balanced Outlook
Sabra Health Care REIT’s analyst price target has edged higher to $21.15 from $20.82, as analysts factor in updated FFO guidance, slightly adjusted revenue growth expectations, a modestly higher assumed profit margin, and a higher future P/E assumption following recent Q4 driven research updates from multiple firms that lifted their targets into a $21 to $23 range. Analyst Commentary Recent Street research on Sabra Health Care REIT reflects a mix of optimism around execution and caution around longer term guidance, which is feeding into the modest move higher in the average price target.Narrative Update • Sep 03
US Senior Living Demand Will Unlock Future Value
Analysts have raised Sabra Health Care REIT’s price target to $20.82, citing strong portfolio performance—highlighted by robust senior housing NOI growth, increased rent coverage, and supportive reimbursement trends—despite elevated leverage and valuation constraints. Analyst Commentary Strong balance sheet and solid year-to-date stock performance, though leverage remains higher than some peers and valuation is at the upper end of historical range, limiting immediate earnings accretion from new acquisitions.Seeking Alpha • Apr 28
Sabra Health Care REIT: 7% Yield And Aging Population Make It A Downturn-Ready Pick
Summary Sabra Health Care REIT's strong fundamentals, 6.62% dividend yield, and low forward multiple make it an attractive investment amid tariff uncertainties and potential recession. The REIT's solid growth in FFO, AFFO, and revenue, driven by increased occupancy rates and NOI growth, highlights its resilience in a challenging economic environment. Sabra's well-positioned balance sheet, with robust liquidity and deleveraging efforts, ensures stability and growth potential, even during economic downturns. Despite potential risks from a recession and healthcare program cuts, Sabra's valuation below peers and continuous improvements make it a compelling investment. Read the full article on Seeking AlphaSeeking Alpha • Mar 19
Sabra Health Care REIT: Come For Income, Stay For Growth
Summary Sabra Health Care REIT, Inc. offers a 6.7% dividend yield, benefiting from strong fundamentals, favorable demographics, and a well-managed balance sheet. Management is guiding for AFFO growth, supported by rising occupancy, stable reimbursement rates, and a robust acquisition pipeline in skilled nursing. SBRA stock trades at a reasonable valuation with a forward P/FFO of 12.2, positioning it for potential market-beating total returns. Read the full article on Seeking AlphaSeeking Alpha • Dec 31
Sabra Health Care REIT: A High-Yielding Gift Just In Time For The New Year
Summary With the FED's rate cut predictions for 2025, Sabra Health Care REIT offers a buying opportunity for long-term investors, especially retirees and income investors. Sabra's solid fundamentals, including improved occupancy rates and a safe 6% dividend yield, make it an attractive investment despite recent market sell-offs. The REIT's balance sheet has strengthened, with Moody's upgrading their outlook to positive, indicating potential for future investment opportunities and price appreciation. Despite potential risks from interest rate fluctuations and economic slowdowns, Sabra Health Care REIT's current valuation and dividend yield present a compelling buy. Read the full article on Seeking AlphaSeeking Alpha • Nov 30
Sabra Health Care REIT: A Promising Value Play In Healthcare Real Estate
Summary Sabra Health Care REIT offers a compelling investment opportunity with a reasonable valuation, trading at 13.6x 2024 FFO and 12.9x 2025 FFO. The company benefits from strong industry fundamentals, including an aging population and growing demand for senior living and healthcare facilities. Q3’24 results showed robust performance with occupancy gains and NOI growth, particularly in the SHOP portfolio, indicating effective operational leverage. Sabra's strong balance sheet, improving credit outlook, and a 6.4% dividend yield make it an attractive option for long-term investors seeking both capital appreciation and dividend safety. Read the full article on Seeking Alpha
New Narrative • Sep 03
Senior Housing And Skilled Nursing's Resilient Growth Amidst Challenges Signals Bright Future
Strong recovery trajectory suggested by occupancy increases in Skilled Nursing and Senior Housing, hinting at enhanced revenue and net income.Seeking Alpha • Jul 24
Sabra Health Care REIT: 2 Catalysts That Should Ignite Solid Growth
Summary High interest rates have pressured businesses, but lower rates are expected to provide relief soon, particularly for REITs. Sabra Health Care REIT is poised to benefit from lower interest rates and an aging population. Despite lower occupancy levels, SBRA is expected to outperform peers with solid growth of 4.75% over the next 3 years. Additionally, dividend growth is expected to resume in 2025 & 2026 since cutting the dividend during COVID. This will also benefit the REIT, likely positively impacting their share price as well. Read the full article on Seeking AlphaSeeking Alpha • May 09
Sabra Healthcare REIT: An Attractive Value Proposition With Moderate Leverage
Summary Sabra Health Care REIT has outperformed the Vanguard Real Estate Index Fund ETF in 2024. I expect the robust performance to continue, with the company confirming its normalized FFO outlook of $1.36/share, up 4.6% Y/Y. Tenant EBITDARM metrics are improving and the company has no exposure to bankrupt Steward Healthcare. Sabra has no significant debt maturities in 2024 and 2025, with a third of the debt locked in at 3.2% until 2031. The market cap rate stands at about 7.4% prior to capex. Read the full article on Seeking AlphaSeeking Alpha • Feb 14
Sabra Health Care REIT: A Risk Worth Taking
Summary Sabra Health Care REIT has strong upside potential with a diverse and stable portfolio, high occupancy rates, and a history of consistent dividend payments. The company is well-positioned to benefit from tailwinds, such as the aging population and rising healthcare spending. However, investors should be aware of headwinds, including regulatory uncertainty and high leverage, as well as the potential for near-term volatility with the upcoming Q4 2023 earnings announcement. Read the full article on Seeking AlphaSeeking Alpha • Sep 13
Sabra Health Care REIT Pays A Good Dividend
Summary I am largely invested in biotech and healthcare companies. I have been building a dividend portion of my portfolio. Sabra offers a high dividend in a healthcare-adjacent space. Sabra Health Care REIT (NASDAQ:SBRA) is a real estate investment trust owning buildings used by the healthcare industry. Its nominal dividend yield is near 8%. The majority of stocks I own are biotech pharma companies. While I have done very well, overall, with them, I have aged into wanting a portfolio that generates some dividends. I like to invest where I have knowledge or analysis skills that give me an advantage. I admit to not being particularly knowledgeable about the REIT space. By looking at Sabra I hope to gain knowledge of a REIT in a commercial space I understand better than retail or residential. In this article I will examine whether Sabra is a good investment for its dividend, but I will not be comparing it to other REITS. I already know it currently pays a higher dividend than any of the pharmaceutical companies or healthcare companies I own. I also note that there are other Health Care REIT stocks to choose from. SBRA data by YCharts Sabra Health Care basics Sabra Health Care REIT is invested in or owns 441 properties and has 75 clients for those properties [SBRA August 2022 presentation, Slide 15]. Most of the properties are skilled nursing or transitional care facilities [Slide 16]. Other significant types of properties owned are behavior health centers and senior housing. Using its equity and leveraging it with some debt, Sabra can lease facilities to operators at relatively attractive rates. It boasts of supporting the expansion of its operator clients while prudently financing its facilities. It emphasizes a growing behavioral health portfolio, including conversion of buildings into addiction treatment centers. For instance, in late 2021 it bought a 132-bed hotel in South Carolina for conversion into an addiction treatment facility. In June 2022 it completed the conversion of a 48-unit memory care facility into an addiction treatment facility. In May 2022 Sabra completed the acquisition of a Canadian senior housing portfolio in a 50/50 joint venture with Sienna Senior Living (TSX: SIA). The acquisition includes 11 senior communities with 1,048 units. Sienna will operate the facilities. The total cost was $243 million. In Q2 $40 million was raised from the sale of eight facilities, an additional two were sold after the quarter ended, and six more were in the process of being sold. Sabra Q2 2022 Results On August 3, 2022, Sabra reported Q2 2022 results. Revenue was $156 million, up 2% from $153 million year-earlier. About $103 million of Q2 revenue was from rents, $49 million from interest or other, and $44 million from residence fees and services. Total expenses jumped y/y to near $130 million, largely because of a $12 million impairment charge. Other expense was $7 million. GAAP income before loss from unconsolidated joint ventures was $19.6 million, down 48% from $37.7 million year-earlier. But the losses from unconsolidated joint ventures declined dramatically from $170 million in Q2 2021 to under $3 million in Q2 2022. All that resulted in GAAP net income of $16.8 million, up from a loss of $132.6 million year-earlier. GAAP EPS was $0.07. Diluted common shares outstanding increased 6% y/y to 231.7 million. Sabra ended the quarter with $67 million in cash. Real estate assets were valued at just over $5 billion. Debt consisted mainly of $1.7 billion in senior unsecured notes, $554 million in term loans, and $142 million in revolving credit debt The company gives much detailed information on AFFO, or adjusted funds from operations. In Q2 that was $88 million or $0.36 per share, down 8% from $0.39 per share in Q2 2021. The press release shows the details of how that was calculated. Note it is a non-GAAP figure. Growth Prospects Revenue growth for the latest quarter was just 2% y/y, not stellar. Since most cash flow is siphoned off for dividends, and there is substantial debt, any growth would likely require new debt, at rates that are currently higher than they have been in years. Except for the Canadian acquisition described above, I would classify Sabra as low-growth until proven otherwise. Dividend and Reliability Sabra declared a $0.30 dividend on August 8, for shareholders of record as of August 17. It was paid out on August 31, so it is a while to wait for the next payment. The $0.30 per quarter level started in May 2020; before that it was $0.45, at least back to the beginning of 2018. Cash use for dividends would have been something under $70 million in the quarter. See also Sabra annual dividend history. Assuming stability, at $1.20 per year and the closing stock price of $15.13 on September 13, 2022, the yield is 7.9%. The dividend payout in Q2 represented 79% of AFFO. But it was $0.23 per share over Q2 GAAP EPS, which is a caution. In April Fitch gave Sabra a BBB- credit rating, indicating it has an adequate ability to meet all financial commitments.Seeking Alpha • Aug 08
Sabra Health Care declares $0.30 dividend
Sabra Health Care (NASDAQ:SBRA) declares $0.30/share quarterly dividend, in line with previous. Forward yield 7.68% Payable Aug. 31; for shareholders of record Aug. 17; ex-div Aug. 16. See SBRA Dividend Scorecard, Yield Chart, & Dividend Growth.Shareholder Returns
| SBRA | US Health Care REITs | US Market | |
|---|---|---|---|
| 7D | -4.1% | -2.6% | 2.0% |
| 1Y | -1.3% | 25.9% | 23.3% |
Return vs Industry: SBRA underperformed the US Health Care REITs industry which returned 30.3% over the past year.
Return vs Market: SBRA underperformed the US Market which returned 25.5% over the past year.
Price Volatility
| SBRA volatility | |
|---|---|
| SBRA Average Weekly Movement | 3.6% |
| Health Care REITs Industry Average Movement | 4.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SBRA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: SBRA's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 58 | Rick Matros | www.sabrahealth.com |
Sabra Health Care REIT, Inc. operates as a self-administered, self-managed real estate investment trust that, through its subsidiaries, owns and invests in real estate serving the healthcare industry throughout the United States and Canada. Sabra Health Care REIT, Inc. is incorporated on May 10th, 2010 and is based in Tustin, United States.
Sabra Health Care REIT, Inc. Fundamentals Summary
| SBRA fundamental statistics | |
|---|---|
| Market cap | US$4.68b |
| Earnings (TTM) | US$156.19m |
| Revenue (TTM) | US$815.66m |
29.1x
P/E Ratio5.6x
P/S RatioIs SBRA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SBRA income statement (TTM) | |
|---|---|
| Revenue | US$815.66m |
| Cost of Revenue | US$295.73m |
| Gross Profit | US$519.94m |
| Other Expenses | US$363.75m |
| Earnings | US$156.19m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.62 |
| Gross Margin | 63.74% |
| Net Profit Margin | 19.15% |
| Debt/Equity Ratio | 95.6% |
How did SBRA perform over the long term?
See historical performance and comparisonDividends
6.6%
Current Dividend Yield79%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/17 03:52 |
| End of Day Share Price | 2026/06/17 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sabra Health Care REIT, Inc. is covered by 31 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Amanda Sweitzer | Baird |
| David Rodgers | Baird |
| Joshua Raskin | Barclays |